Diagnostic and Prognostic Value of Serum Vitronectin and Galectin-3 levels in Thyroid Tumors

Abstract

Objective: Increased expression of Galectin-3(Gal-3) and Vitronectin (VN) molecules has been the subject of research, since it may be a biological marker that can be used for the separation of benign and malignant tissues. We aimed to evaluate serum Gal-3 and VN expression levels in the presence of thyroid tissue, and evaluate the predictive and prognostic value of these molecules in the differential diagnosis of malignant tissues. Materials and Methods: 44 patients with thyroid nodules were included in this prospective study. Benign and malignant lesions were distinguished from thyroidectomy materials. Results: Mean preoperative Gal-3 and VN values measured in malignant lesions were statistically significantly higher than preoperative Gal-3 and VN values in benign lesions (p-values: 0.007 and 0.009, respectively). Also, mean Gal-3 and VN values measured in serum were significantly reduced after operation compared to preoperative values (p-values<0.001 and 0.001, respectively). Mean preoperative Gal-3 and VN values were found statistically significantly higher if there is capsular invasion (p-values: 0.033 and 0.026, respectively). Conclusion: The serum Gal-3 and VN concentrations are increased in thyroid cancer and in the presence of capsular invasion. And also decreased during the postoperative period significantly. Our findings will contribute to the literature in order to improve correct diagnosis and mortality rates in thyroid lesions.

Keywords

• Thyroid cancer
• thyroid nodules
• Vitronectin
• Galectin-3
• Prognosis
• Diagnosis

References

1. Kitahara, C. M., K Rmendiné Farkas, D., Jørgensen, J. O. L., Cronin-Fenton, D., & Sørensen, H. T. (2018). Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study. The Journal of clinical endocrinology and metabolism, 103(6), 2216–2224. https://doi.org/10.1210/jc.2017-02599
2. Wang, L., & Guo, X. L. (2016). Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 78, 165–171. https://doi.org/10.1016/j.biopha.2016.01.014
3. Trimboli, P., Virili, C., Romanelli, F., Crescenzi, A., & Giovanella, L. (2017). Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis. International journal of molecular sciences, 18(8), 1756. https://doi.org/10.3390/ijms18081756
4. DE OLIVEIRA, Joana T.; RIBEIRO, Cláudia; GÄRTNER, Fátima. Role of Galectin-3 in Cancer Metastasis. Glycobiology Insights, 2015;5:1-13.
5. Hao, W., Zhang, X., Xiu, B., Yang, X., Hu, S., Liu, Z., Duan, C., Jin, S., Ying, X., Zhao, Y., Han, X., Hao, X., Fan, Y., Johnson, H., Meng, D., Persson, J. L., Zhang, H., Feng, X., & Huang, Y. (2016). Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37(7), 8909–8916. https://doi.org/10.1007/s13277-015-4750-y
6. Ortega-Martínez, I., Gardeazabal, J., Erramuzpe, A., Sanchez-Diez, A., Cortés, J., García-Vázquez, M. D., Pérez-Yarza, G., Izu, R., Luís Díaz-Ramón, J., de la Fuente, I. M., Asumendi, A., & Boyano, M. D. (2016). Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma. International journal of cancer, 139(7), 1598–1607. https://doi.org/10.1002/ijc.30202
7. Zhu, W., Li, W., Yang, G., Fu, C., Jiang, G., & Hu, Q. (2015). Vitronectin silencing inhibits hepatocellular carcinoma in vitro and in vivo. Future oncology (London, England), 11(2), 251–258. https://doi.org/10.2217/fon.14.202
8. Pola, C., Formenti, S. C., & Schneider, R. J. (2013). Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells. Cancer research, 73(14), 4571–4578. https://doi.org/10.1158/0008-5472.CAN-13-0218

9. Kitahara, C. M., & Sosa, J. A. (2016). The changing incidence of thyroid cancer. Nature reviews. Endocrinology, 12(11), 646–653. https://doi.org/10.1038/nrendo.2016.110
10. Liu, H., & Lin, F. (2015). Application of immunohistochemistry in thyroid pathology. Archives of pathology & laboratory medicine, 139(1), 67–82. https://doi.org/10.5858/arpa.2014-0056-RA
11. Sumana, B. S., Shashidhar, S., & Shivarudrappa, A. S. (2015). Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms. Journal of clinical and diagnostic research : JCDR, 9(11), EC07–EC11. https://doi.org/10.7860/JCDR/2015/16277.6760
12. Ruvolo P. P. (2016). Galectin 3 as a guardian of the tumor microenvironment. Biochimica et biophysica acta, 1863(3), 427–437. https://doi.org/10.1016/j.bbamcr.2015.08.008
13. Siderova, Mira, et al. Galectin-3 expression in thyroid tumors. Scripta Scientifica Medica, 2016;48.3: 58-64.
14. Weihui LU, et al. The role of Galectin-3 in promoting metastasis of papillary thyroid carcinoma. China Oncology, 2017;27.10:775-781.
15. Tang, W., Huang, C., Tang, C., Xu, J., & Wang, H. (2016). Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis. OncoTargets and therapy, 9, 455–460. https://doi.org/10.2147/OTT.S94514
16. Wang, L., & Guo, X. L. (2016). Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 78, 165–171. https://doi.org/10.1016/j.biopha.2016.01.014
17. Li, J., Vasilyeva, E., & Wiseman, S. M. (2019). Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer. Expert review of anticancer therapy, 19(12), 1017–1027. https://doi.org/10.1080/14737140.2019.1693270
18. Inohara, H., Segawa, T., Miyauchi, A., Yoshii, T., Nakahara, S., Raz, A., Maeda, M., Miyoshi, E., Kinoshita, N., Yoshida, H., Furukawa, M., Takenaka, Y., Takamura, Y., Ito, Y., & Taniguchi, N. (2008). Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochemical and biophysical research communications, 376(3), 605–610. https://doi.org/10.1016/j.bbrc.2008.09.041
19. Makki, F. M., Taylor, S. M., Shahnavaz, A., Leslie, A., Gallant, J., Douglas, S., Teh, E., Trites, J., Bullock, M., Inglis, K., Pinto, D. M., & Hart, R. D. (2013). Serum biomarkers of papillary thyroid cancer. Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 42(1), 16. https://doi.org/10.1186/1916-0216-42-16
20. Yoshimura, A., Sawada, K., Nakamura, K., Kinose, Y., Nakatsuka, E., Kobayashi, M., Miyamoto, M., Ishida, K., Matsumoto, Y., Kodama, M., Hashimoto, K., Mabuchi, S., & Kimura, T. (2018). Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC cancer, 18(1), 1065. https://doi.org/10.1186/s12885-018-4974-5
21. Yang, X. P., Zhou, L. X., Yang, Q. J., Liu, L., Cai, Y., & Ma, S. L. (2016). Diagnostic and prognostic roles of serum vitronectin in hepatitis B-related hepatocellular carcinoma. Cancer biomarkers : section A of Disease markers, 17(3), 271–279. https://doi.org/10.3233/CBM-160639
22. Hao, W., Zhang, X., Xiu, B., Yang, X., Hu, S., Liu, Z., Duan, C., Jin, S., Ying, X., Zhao, Y., Han, X., Hao, X., Fan, Y., Johnson, H., Meng, D., Persson, J. L., Zhang, H., Feng, X., & Huang, Y. (2016). Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37(7), 8909–8916. https://doi.org/10.1007/s13277-015-4750-y
23. Niu, Y., Zhang, L., Bi, X., Yuan, S., & Chen, P. (2016). Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer. Urology journal, 13(1), 2527–2532.